SELLAS Life Sciences Group (SLS) to Release Quarterly Earnings on Tuesday

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) is projected to announce its Q1 2025 earnings results before the market opens on Tuesday, May 13th. Analysts expect SELLAS Life Sciences Group to post earnings of ($0.11) per share for the quarter.

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last posted its earnings results on Thursday, March 20th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.03. During the same period in the prior year, the firm earned ($1.34) earnings per share. On average, analysts expect SELLAS Life Sciences Group to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

SELLAS Life Sciences Group Price Performance

SLS traded up $0.03 during midday trading on Friday, reaching $1.71. 438,373 shares of the company's stock traded hands, compared to its average volume of 2,320,852. The stock has a market capitalization of $161.68 million, a price-to-earnings ratio of -2.48 and a beta of 2.34. SELLAS Life Sciences Group has a 52 week low of $0.77 and a 52 week high of $1.85. The firm has a fifty day moving average of $1.26 and a two-hundred day moving average of $1.18.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.